Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole for Oxaliplatin Induced Neuropathy in Cancer Patients
NCT05680870Phase 3Completed
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of omeprazole in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms). Primary endpoints: Acute peripheral neuropathy at 6 months and Chronic peripheral neuropathy at 6 months. Started Feb 2023; status: completed.
02
Drugs
omeprazole
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05680870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680870.